ReviewGland surgery2026
Treatment strategies for unilateral papillary thyroid carcinoma with ipsilateral cervical lymph node metastasis: a narrative review.
Review in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Unilateral papillary thyroid carcinoma (PTC) with ipsilateral cervical lymph-node metastasis carries intermediate-to-high recurrence risk. Although total thyroidectomy is conventionally recommended by multiple clinical guidelines, accumulating real‑world evidence has triggered ongoing debates regarding surgical extent, neck dissection scope, adjuvant radioactive iodine administration and molecular‑guided risk stratification. This narrative review intends to synthesize contemporary clinical evidence and provide references for individualized therapeutic decision‑making for this specific patient population. Methods: Literature was retrieved from PubMed, Embase, and Web of Science up to January 2026. English articles were screened by two reviewers through consensus. This is a narrative review without formal systematic-review procedures. Key Content and Findings: For properly-selected patients, lobectomy provides similar oncological outcomes as total thyroidectomy with fewer complications. Unilateral central neck dissection plus selective lateral neck dissection balances tumour control and surgical morbidity. Aggressive pathological variants and concurrent B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E/telomerase reverse transcriptase (TERT) promoter dual mutations indicate elevated recurrence and mortality risk. Radioactive iodine (RAI) ablation ought to be determined by integrated risk assessment rather than routine application. Lymph‑node yield and lymph‑node ratio serve as key prognostic markers reflecting dissection quality and recurrence likelihood. Serum thyroglobulin, interfered by thyroglobulin antibodies, remains the core surveillance biomarker. Conclusions: Risk‑stratified individualized management is strongly recommended for unilateral PTC patients with ipsilateral cervical lymph‑node metastasis. This review may facilitate clinical practice. Nevertheless, most available evidence comes from retrospective studies; further high‑quality prospective investigations are required to refine treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.